{"filing":{"accession_number":"0001193125-26-256445","cik":"0001572616","ticker":"GUTS","company_name":"FRACTYL HEALTH, INC.","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"guts-20260604.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1572616/000119312526256445/guts-20260604.htm"},"events":[{"id":6776,"run_id":5937,"accession_number":"0001193125-26-256445","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Fractyl Health announced positive one-year clinical trial results from the REVEAL-1 Cohort for its Revita procedure in obesity treatment, demonstrating 78% maintenance of GLP-1-induced weight loss with a favorable safety profile.","company_name":"FRACTYL HEALTH, INC.","ticker":"GUTS","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4295,"accession_number":"0001193125-26-256445","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.45,"reasoning":"The filing discloses only that a press release was issued on June 4, 2026 and furnished as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure). The actual content of the press release is not provided in the section text, making it impossible to determine the specific event type. Without visibility into what the press release announces, I cannot classify this as earnings_release, exec_departure, exec_appointment, or any other specific event category. The boilerplate language about Section 18 liability and incorporation by reference is standard for Regulation FD disclosures and does not itself constitute a material event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:54:58.811800+00:00","company_name":"","ticker":null,"filing_date":""},{"id":4296,"accession_number":"0001193125-26-256445","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces positive one-year clinical trial results from the REVEAL-1 Cohort for Fractyl's Revita procedure in obesity treatment, showing 78% maintenance of GLP-1-induced weight loss and a favorable safety profile. While this is material clinical progress for a medical device company, it does not fit neatly into the more specific event categories (not an earnings release, M\u0026A activity, impairment, litigation, or going-concern issue), making \"other_material\" the most appropriate classification for this clinical milestone announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:54:58.811800+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4295,"accession_number":"0001193125-26-256445","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.45,"reasoning":"The filing discloses only that a press release was issued on June 4, 2026 and furnished as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure). The actual content of the press release is not provided in the section text, making it impossible to determine the specific event type. Without visibility into what the press release announces, I cannot classify this as earnings_release, exec_departure, exec_appointment, or any other specific event category. The boilerplate language about Section 18 liability and incorporation by reference is standard for Regulation FD disclosures and does not itself constitute a material event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:54:58.811800+00:00","company_name":"FRACTYL HEALTH, INC.","ticker":"GUTS","filing_date":"2026-06-04"},{"id":4296,"accession_number":"0001193125-26-256445","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces positive one-year clinical trial results from the REVEAL-1 Cohort for Fractyl's Revita procedure in obesity treatment, showing 78% maintenance of GLP-1-induced weight loss and a favorable safety profile. While this is material clinical progress for a medical device company, it does not fit neatly into the more specific event categories (not an earnings release, M\u0026A activity, impairment, litigation, or going-concern issue), making \"other_material\" the most appropriate classification for this clinical milestone announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:54:58.811800+00:00","company_name":"FRACTYL HEALTH, INC.","ticker":"GUTS","filing_date":"2026-06-04"}]}